People · Operator
Named in public records as an officer, director or promoter · active 2024–2026 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BiomX Inc. | — | Pharmaceuticals | Series C | $72.3M | $16.9M | 2024 |
Jesse Goodman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jesse Goodman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Leff | 1 | 11 |
| PAUL SEKHRI | 1 | 7 |
| Edward Williams | 1 | 3 |
| Jonathan Solomon | 1 | 3 |
| Lynne Sullivan | 1 | 3 |
| Gregory Merril | 1 | 2 |
| Jonas Grossman | 1 | 2 |
| Assaf Oron | 1 | 1 |
| Avi Gabay | 1 | 1 |
| Lynne Eitan Sullivan | 1 | 1 |
| Gbola Amusa | 1 | 1 |
| Marina Eitan Wolfson | 1 | 1 |
| Jonathan Eitan Solomon | 1 | 1 |
| Sailaja Puttagunta | 1 | 1 |
| Alan Moses | 1 | 1 |
| Merav Bassan | 1 | 1 |
| Eddie Williams | 1 | 1 |
| Susan Blum | 1 | 1 |
| Russell Greig | 1 | 1 |
| Marina Wolfson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.